RING finger protein 38 induces the drug resistance of cisplatin in non-small-cell lung cancer.
RING finger protein 38
cell apoptosis
cisplatin resistance
non-small-cell lung cancer
ubiquitin-proteasome system
Journal
Cell biology international
ISSN: 1095-8355
Titre abrégé: Cell Biol Int
Pays: England
ID NLM: 9307129
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
28
04
2020
revised:
26
06
2020
accepted:
22
07
2020
pubmed:
25
7
2020
medline:
1
9
2021
entrez:
25
7
2020
Statut:
ppublish
Résumé
Cisplatin resistance of non-small-cell lung cancer (NSCLC) needs to be well elucidated. RING finger protein (RNF38) has been proposed as a biomarker of NSCLC poor prognosis. However, its role in drug resistance in NSCLC is poorly understood. RNF38 expression was detected in normal lung epithelial cell and four NSCLC cell lines. RNF38 was stably overexpressed in A549 and H460 cells or silenced in H1975 and cisplatin-resistant A549 cells (A549-CDDP resistant) using lentiviral vectors. RNF38 expression levels were determined using quantitative real-time polymerase chain reaction and western blotting analysis. Cell viability in response to different concentrations of cisplatin was evaluated by Cell Counting Kit-8 assay. RNF38 expression levels were markedly elevated in NSCLC cells and cells harboring high RNF38 were less sensitive to cisplatin. Overexpression of RNF38 reduced, while RNF38 silencing increased the drug sensitivity of cisplatin in NSCLC cells. Cisplatin-resistant cells expressed high RNF38 level. RNF38 silencing promoted cell apoptosis and enhanced the drug sensitivity of cisplatin in cisplatin-resistant NSCLC cells. These findings indicate that RNF38 might induce cisplatin resistance of NSCLC cells via promoting cell apoptosis and RNF38 could be a novel target for rectify cisplatin resistance in NSCLC cases.
Substances chimiques
Antineoplastic Agents
0
Carrier Proteins
0
RNF38 protein, human
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-294Subventions
Organisme : Major State Basic Research Development Program of China
ID : 2017YFC0907904
Informations de copyright
© 2020 International Federation for Cell Biology.
Références
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., … He, J. (2016). Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132.
Fennell, D. A., Summers, Y., Cadranel, J., Benepal, T., Christoph, D. C., Lal, R., … Ferry, D. (2016). Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treatment Reviews, 44, 42-50.
Gao, Y., Cai, A., Xi, H., Li, J., Xu, W., Zhang, Y., … Chen, L. (2017). Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-beta/catenin signaling pathway. Stem Cell Research & Therapy, 8, 98.
Geng, R., Tan, X., Wu, J., Pan, Z., Yi, M., Shi, W., … Chen, S. (2017). RNF183 promotes proliferation and metastasis of colorectal cancer cells via activation of NF-kappaB-IL-8 axis. Cell Death & Disease, 8, e2994.
Huang, Z., Yang, P., Ge, H., Yang, C., Cai, Y., Chen, Z., … Wang, H. (2020). RING finger protein 38 mediates LIM domain binding 1 degradation and regulates cell growth in colorectal cancer. OncoTargets and Therapy, 13, 371-379.
Ke, B., Wei, T., Huang, Y., Gong, Y., Wu, G., Liu, J., … Shi, L. (2019). Interleukin-7 resensitizes non-small-cell lung cancer to cisplatin via inhibition of ABCG2. Mediators of Inflammation, 2019, 7241418.
Kuo, D. Y., Blank, S. V., Christos, P. J., Kim, M., Caputo, T. A., Pothuri, B., … Einstein, M. H. (2010). Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study. Gynecologic Oncology, 116, 442-446.
Li, Y., Ma, C., Zhou, T., Liu, Y., Sun, L., & Yu, Z. (2016). TRIM65 negatively regulates p53 through ubiquitination. Biochemical and Biophysical Research Communications, 473, 278-282.
Lipkowitz, S., & Weissman, A. M. (2011). RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nature Reviews Cancer, 11, 629-643.
Liu, H., Chen, W., Liang, C., Chen, B. W., Zhi, X., Zhang, S., … Liang, T. (2015). WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation. Cancer Letters, 361, 218-225.
Lu, Y., Han, D., Liu, W., Huang, R., Ou, J., Chen, X., … Song, W. (2018). RNF138 confers cisplatin resistance in gastric cancer cells via activating Chk1 signaling pathway. Cancer Biology & Therapy, 19, 1128-1138.
Martelli, L., Di Mario, F., Ragazzi, E., Apostoli, P., Leone, R., Perego, P., & Fumagalli, G. (2006). Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Biochemical Pharmacology, 72, 693-700.
Matsuura, K., Huang, N. J., Cocce, K., Zhang, L., & Kornbluth, S. (2017). Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin. Oncogene, 36, 1698-1706.
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., … Siegel, R. L. (2019). Cancer treatment and survivorship statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 363-385.
Narayanan, S., Cai, C. Y., Assaraf, Y. G., Guo, H. Q., Cui, Q., Wei, L., … Chen, Z. S. (2020). Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resistance Updates, 48, 100663.
Patel, J. D., Paz-Ares, L., Zinner, R. G., Barlesi, F., Koustenis, A. G., & Obasaju, C. K. (2018). Pemetrexed continuation maintenance phase 3 trials in nonsquamous, non-small-cell lung cancer: Focus on 2-year overall survival and continuum of care. Clinical Lung Cancer, 19, e823-e830.
Sheren, J. E., & Kassenbrock, C. K. (2013). RNF38 encodes a nuclear ubiquitin protein ligase that modifies p53. Biochemical and Biophysical Research Communications, 440, 473-478.
Testa, U., Castelli, G., & Pelosi, E. (2018). Lung cancers: Molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers, 10, 248.
Wang, X., Bao, Y., Dong, Z., Chen, Q., Guo, H., Ziang, C., & Shao, J. (2017). WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas. Oncotarget, 8, 49033-49043.
Xiang, P., Sun, Y., Liu, Y., Shu, Q., & Zhu, Y. (2018). Really interesting new gene finger protein 121 is a tumor suppressor of renal cell carcinoma. Gene, 676, 322-328.
Xiong, D., Zhu, S. Q., Wu, Y. B., Jin, C., Jiang, J. H., Liao, Y. F., … Ding, J. Y. (2018). Ring finger protein 38 promote non-small cell lung cancer progression by endowing cell EMT phenotype. Journal of Cancer, 9, 841-850.
Xu, X., Han, K., Tang, X., Zeng, Y., Lin, X., Zhao, Y., … Mao, X. (2016). The ring finger protein RNF6 induces leukemia cell proliferation as a direct target of pre-B-cell leukemia homeobox 1. Journal of Biological Chemistry, 291, 9617-9628.
Yang, W., Xiao, W., Cai, Z., Jin, S., & Li, T. (2020). miR-1269b Drives Cisplatin Resistance of Human Non-Small Cell Lung Cancer via Modulating the PTEN/PI3K/AKT Signaling Pathway. OncoTargets and Therapy, 13, 109-118.
Yin, C., Lin, X., Wang, Y., Liu, X., Xiao, Y., Liu, J., … Zhang, P. (2020). FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer. Cellular Oncology, 43, 395-407.
Zhang, J., Wu, H., Yi, B., Zhou, J., Wei, L., Chen, Y., & Zhang, L. (2018). RING finger protein 38 induces gastric cancer cell growth by decreasing the stability of the protein tyrosine phosphatase SHP-1. FEBS Letters, 592, 3092-3100.
Zhu, H., Luo, H., Zhang, W., Shen, Z., Hu, X., & Zhu, X. (2016). Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design, Development and Therapy, 10, 1885-1895.